Sartorius Cuts 2023 Guidance on Lower Preliminary Sales Results
13 Oktober 2023 - 8:00AM
Dow Jones News
By Andrea Figueras
Sartorius downgraded its 2023 outlook after it posted
preliminary lower sales and earnings for the first nine months of
the year.
The German life science group now expects sales to fall around
17%, while it previously forecast a decline in the low to mid-teens
percentage range, the company said late Thursday.
It also cut its estimates for the underlying earnings before
interest, taxes, depreciation and amortization margin to slightly
above 28%, after previously forecasting a margin of around 30%, it
said.
For next year, it expects profitable growth and will issue a
quantitative guidance with the 2023 full-year results in January,
when it will also update its midterm targets.
Consolidated revenue fell around 16% to 2.5 million euros ($2.6
million) in constant currencies, according to the company's
preliminary results for the first nine months of the year.
The underlying Ebitda margin dropped to EUR733 million due to
volume and product mix effects, from EUR1.05 billion during the
same period last year, it said.
Sartorius will publish its nine-month results on Oct. 19.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
October 13, 2023 01:45 ET (05:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sartorius (TG:SRT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sartorius (TG:SRT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
